Goldman Sachs’s Aldeyra Therapeutics ALDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $918K | Buy |
543,146
+237,440
| +78% | +$1.04M | ﹤0.01% | 5148 |
|
|
2025
Q4 | $1.58M | Buy |
305,706
+122,763
| +67% | +$631K | ﹤0.01% | 4788 |
|
|
2025
Q3 | $955K | Buy |
182,943
+43,329
| +31% | +$226K | ﹤0.01% | 5059 |
|
|
2025
Q2 | $535K | Buy |
139,614
+15,249
| +12% | +$39.4K | ﹤0.01% | 5119 |
|
|
2025
Q1 | $715K | Sell |
124,365
-115,969
| -48% | -$686K | ﹤0.01% | 4941 |
|
|
2024
Q4 | $1.2M | Buy |
240,334
+95,506
| +66% | +$490K | ﹤0.01% | 4681 |
|
|
2024
Q3 | $781K | Buy |
144,828
+39,901
| +38% | +$190K | ﹤0.01% | 4807 |
|
|
2024
Q2 | $347K | Buy |
104,927
+13,210
| +14% | +$51.7K | ﹤0.01% | 5019 |
|
|
2024
Q1 | $300K | Sell |
91,717
-55,763
| -38% | -$183K | ﹤0.01% | 4971 |
|
|
2023
Q4 | $518K | Sell |
147,480
-21,203
| -13% | -$65.4K | ﹤0.01% | 4731 |
|
|
2023
Q3 | $1.13M | Sell |
168,683
-28,753
| -15% | -$213K | ﹤0.01% | 4186 |
|
|
2023
Q2 | $1.66M | Sell |
197,436
-89,807
| -31% | -$885K | ﹤0.01% | 4003 |
|
|
2023
Q1 | $2.85M | Buy |
287,243
+263,493
| +1,109% | +$1.86M | ﹤0.01% | 3565 |
|
|
2022
Q4 | $165K | Sell |
23,750
-164,557
| -87% | -$941K | ﹤0.01% | 5364 |
|
|
2022
Q3 | $1M | Sell |
188,307
-996,277
| -84% | -$5.98M | ﹤0.01% | 4502 |
|
|
2022
Q2 | $4.73M | Sell |
1,184,584
-206,434
| -15% | -$710K | ﹤0.01% | 3189 |
|
|
2022
Q1 | $6.18M | Buy |
1,391,018
+1,288,353
| +1,255% | +$5.13M | ﹤0.01% | 3152 |
|
|
2021
Q4 | $410K | Sell |
102,665
-19,390
| -16% | -$148K | ﹤0.01% | 5498 |
|
|
2021
Q3 | $1.07M | Sell |
122,055
-885,564
| -88% | -$8.13M | ﹤0.01% | 4687 |
|
|
2021
Q2 | $11.4M | Buy |
1,007,619
+931,972
| +1,232% | +$11.2M | ﹤0.01% | 2563 |
|
|
2021
Q1 | $899K | Buy |
75,647
+32,712
| +76% | +$377K | ﹤0.01% | 4695 |
|
|
2020
Q4 | $295K | Buy |
42,935
+13,374
| +45% | +$93.9K | ﹤0.01% | 4893 |
|
|
2020
Q3 | $219K | Sell |
29,561
-7,512
| -20% | -$48.5K | ﹤0.01% | 4875 |
|
|
2020
Q2 | $155K | Buy |
37,073
+9,124
| +33% | +$33.3K | ﹤0.01% | 4882 |
|
|
2020
Q1 | $69K | Sell |
27,949
-71,124
| -72% | -$320K | ﹤0.01% | 4995 |
|
|
2019
Q4 | $575K | Buy |
99,073
+18,817
| +23% | +$109K | ﹤0.01% | 4420 |
|
|
2019
Q3 | $423K | Buy |
80,256
+64,019
| +394% | +$345K | ﹤0.01% | 4520 |
|
|
2019
Q2 | $97K | Buy |
16,237
+3,864
| +31% | +$29.1K | ﹤0.01% | 4928 |
|
|
2019
Q1 | $112K | Sell |
12,373
-6,166
| -33% | -$52.4K | ﹤0.01% | 4913 |
|
|
2018
Q4 | $154K | Sell |
18,539
-8,884
| -32% | -$91K | ﹤0.01% | 4898 |
|
|
2018
Q3 | $378K | Buy |
+27,423
| New | +$222K | ﹤0.01% | 4573 |
|
|
2018
Q2 | – | Sell |
-15,567
| Closed | -$117K | – | 5626 |
|
|
2018
Q1 | $117K | Buy |
+15,567
| New | +$118K | ﹤0.01% | 5224 |
|
Other funds holding ALDX
KCM
VCM
KCM
6CM
Goldman Sachs's ALDX Position: Q1 2026 in Review
Goldman Sachs increased its Aldeyra Therapeutics (ALDX) stake by 78% in Q1 2026, buying an estimated $1.04M and bringing the position to 543,146 shares worth $918K. The position accounts for ﹤0.01% of the portfolio, ranked #5148.
Goldman Sachs first reported a position in ALDX in Q1 2018 and has held it in 32 quarters since. The position peaked at $11.4M in Q2 2021. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.
- Goldman Sachs held 543,146 shares of Aldeyra Therapeutics worth $918K as of Q1 2026.
- Goldman Sachs bought 237,440 Aldeyra Therapeutics shares in Q1 2026, an estimated $1.04M.
- Aldeyra Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5148 holding.
- Goldman Sachs first reported a position in Aldeyra Therapeutics in Q1 2018 and has held it in 32 quarters since.
- Goldman Sachs's Aldeyra Therapeutics position peaked at $11.4M in Q2 2021.
- 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.